Short CV

2020_Ramón y Cajal investigator, R3 accreditation, Centre for Genomic Regulation (CRG), Barcelona (Spain)
2016_ Staff Scientist, Centre for Genomic Regulation (CRG), Barcelona (Spain)
2014_ Beatriu de Pinós fellow, Centre for Genomic Regulation (CRG), Barcelona (Spain)
2009_ FEBS Long-term fellow, Karolinska Institutet, Stockholm (Sweden)
2007_ Ph.D. in Biochemistry, University of Barcelona (UB), thesis carried our at the CRG, Barcelona (Spain)
2004_ Master of Advanced Studies, University of Barcelona (UB), Barcelona (Spain)
2002_ Graduate student, Institut de Recerca Oncològica (IRO, now IDIBELL), Barcelona (Spain)
2001_ B.Sc. in Biochemistry, University of Barcelona (UB), Barcelona (Spain)

Summary

During embryo development, every cell arises from a single cell with a unique genome. Different parts of this genome are switched on or kept silent at different times and in different cells, and this balance drives cell fate and maintains cellular identity. When it fails, unscheduled gene expression programs cause severe developmental and pediatric diseases. 

We study how cells select and activate specific regions of the genome, how this information is remembered across cell divisions, and how it is coupled to the changing environment. To do so, we combine embryonic stem cells, organoids, patient-derived samples and mouse models with the latest biochemical, genetic and computational technologies. 

Our translational epigenomics program focuses on epigenetic alterations linked to inherited methylation disorders and pediatric tumors. To bring our discoveries to patients, we work closely with hospitals and biotech companies. Our goal is to lay the foundations for conceptually new therapies for human developmental diseases and pediatric cancer.

Funding acknowledgements

The project "Targeting methylation defects in inherited metabolic disorders: mechanistic insights and therapeutic advances" (ref. PI25/01811) has been granted by the Instituto de Salud Carlos III (ISCIII) and by FEDER. Period: 01/01/2026 to 31/12/2028

---

The project "Advancing Precision Medicine in Pediatric Glioma: Engineering Stem Cell-Based Organoids for Targeted Therapies (GlioStem)" (ref. CNS2023-145726, MICIU/AEI/10.13039/501100011033) has been granted by the Agencia Estatal de Investigación (AEI), the Ministerio de Ciencia, Innovación y Universidades (MICIU) and by the European Union NextGenerationEU/PRTR. Period: 01/04/2024 to 31/03/2025 

---

The project "Metabolic sensitization of chromatin as a therapeutic approach for pediatric diffuse midline glioma" (ref. PI22/01837) has been granted by the Instituto de Salud Carlos III (ISCIII) and by FEDER. Period: 01/01/2023 to 31/12/2025

---

The project "AHCY dysfunction in human metabolic disorders and infertility: Novel diagnostic tools and therapeutic approaches" (ref. PI19/01814) has been granted by the Instituto de Salud Carlos III (ISCIII) and by FEDER. Period: 01/01/2020 to 31/12/2022 Ref.: PI19/01814

---

The project "Chromatin biology in embryo development and human diseases" (ref. RYC2018-025002-I, MCIN/AEI/10.13039/501100011033) has been granted by the Agencia Estatal de Investigación (AEI), the Ministerio de Ciencia e Innovación (MCIN) and by the European Social Fund.